Curated CRC research, accessible, accurate, actionable

The CRC Digest

Sunday, October 11, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ● REGULATORY

  FDA approves atezolizumab plus chemotherapy for Stage III dMMR colon cancer

  The FDA approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of adult and pediatric patients two years and older with Stage III mismatch repair deficient colon cancer. Efficacy was evaluated in the ATOMIC/ML39057 trial, which showed a 50% reduction in risk of disease recurrence or death. (FDA)

• ◆ TRIAL DATA

  ATOMIC trial shows 86% three-year disease-free survival with atezolizumab combination

  At a median follow-up of 40.9 months in the ATOMIC trial, the 3-year disease-free survival rate was 86.3% in patients receiving atezolizumab plus mFOLFOX6 compared with 76.2% in those receiving chemotherapy alone. (Targeted Oncology)

• ▸ TREATMENT

  c-Met antibody-drug conjugate receives FDA breakthrough designation for refractory metastatic CRC

  Telisotuzumab adizutecan, a c-Met–directed antibody-drug conjugate, received FDA breakthrough therapy designation in combination with bevacizumab for adults with refractory metastatic colorectal cancer who have previously received fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF antibody, and when indicated, an anti-EGFR antibody. (Targeted Oncology)

• ♥ LIVING WITH CRC

  Survey finds 31% of metastatic CRC patients report delayed diagnosis

  In a US survey of 344 adults with metastatic colorectal cancer, 31% reported that their diagnosis was delayed, with 83% wishing more information had been provided by their health-care provider at diagnosis. (Future Oncology)

This week's research includes a major regulatory milestone for Stage III dMMR colon cancer and ongoing investigation into treatment resistance mechanisms and early-onset disease.

Editorial note: one or more studies referenced above are preprints and have not yet been peer-reviewed; findings are preliminary and may change before formal publication.